Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropsychiatric and Oncological Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PVALB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human PVALB Protein (Wild-Type & Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PVALB Products |
| Gene Delivery | PVALB Promise-ORF / Lentivirus Full-length ORF for stable cell lines and calcium buffering assays. |
View PVALB Products |
| Benchmark Ab | Anti-PVALB Recombinant Antibody Recombinant positive control for IHC, Western Blot, and Flow Cytometry. |
View PVALB Products |
| Validator | PVALB siRNA Set For knockdown verification in functional studies. |
View PVALB Products |
| Related Target A | CALB1 (Calbindin 1) Homologous EF-hand calcium-binding protein; critical for selectivity counter-screening. |
View CALB1 Products |
| Related Target B | CALB2 (Calretinin) Key interneuron marker; used to evaluate off-target profile in neuropsychiatric panels. |
View CALB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-family off-target binding (EF-hand homology) | Recombinant CALB1 and CALB2 proteins available with >95% purity for counter-screening. |
| Calcium-dependent conformational changes | Sequence-verified wild-type and calcium-binding loop mutants (EF-hand mutants) for conformational assay controls. |
| Lack of Controls | High-affinity recombinant benchmark antibodies included for assay standardization. |
| False Positives | Sequence-specific siRNA sets included for target knockdown validation. |
Live Parvalbumin (PVALB) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Parvalbumin (PVALB) networks is gaining momentum, particularly in the realm of neuropsychiatric disorders and specific oncological indications. PVALB-positive (PV+) GABAergic interneurons play a vital role in maintaining cortical gamma oscillations, which are disrupted in schizophrenia, autism spectrum disorders (ASD), and epilepsy. Rather than targeting PVALB directly with systemic small molecules, current clinical strategies focus on modulating PV+ interneuron activity via synaptic receptors (e.g., GABA-A alpha-5 receptors, Kv3 potassium channels) or utilizing gene therapy to restore PVALB expression levels.
In oncology, PVALB serves as an essential diagnostic biomarker, distinguishing chromophobe renal cell carcinoma (ChRCC) from oncocytoma. As the field transitions toward precision medicine, high-affinity reagents that can distinguish PVALB from other EF-hand calcium-binding proteins are paramount for both diagnostic assay development and targeted therapeutic monitoring.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic Institutions, Biotech Startups | Epilepsy, Schizophrenia | Lentivirus Premade Particles for stable cell line construction and functional rescue assays. |
| Small Molecule (Synaptic Modulators) | Autifony Therapeutics, Roche, Biogen | Schizophrenia, Cognitive Impairment | Selectivity assays using recombinant PVALB, CALB1, and CALB2 to ensure no direct off-target calcium chelation. |
| Diagnostic Antibodies (IHC/IVD) | Roche Tissue Diagnostics, Abbott, Leica | Renal Cell Carcinoma, Neuro-biomarkers | Ultra-pure antigen validation to eliminate cross-reactivity with homologous calcium-binding proteins. |